The short answer
Active surveillance is a structured monitoring program with PSA, MRI, and repeat biopsies, designed to keep curative treatment available while avoiding its side effects unnecessarily.
Active surveillance is monitoring aimed at cure held in reserve, and is different from watchful waiting, which manages symptoms only.
In the ProtecT trial at 15 years, prostate-cancer-specific survival was about 97% across active monitoring, surgery, and radiotherapy.
Metastases were more common with monitoring (9.4%) than after surgery (4.7%) or radiotherapy (5.0%), which is the honest trade-off.
About a quarter of men in the ProtecT monitoring arm were alive with no prostate cancer treatment at all at the end of follow-up.
Choose how you want to understand this
The full explanation.
Active surveillance is not doing nothing
Active surveillance is a structured monitoring program. It is used for low-risk prostate cancer, and for some favorable intermediate-risk cancer. NCI defines it as "closely following a patient's condition without giving any treatment unless there are changes in test results." The aim is to catch signs of progression early.
It is deliberately different from watchful waiting. Watchful waiting is looser monitoring. It is usually for men whose age or other health conditions mean curative treatment would not benefit them. The goal there is symptom control if problems develop. Active surveillance is aimed at cure, held in reserve. The whole point is that treatment stays available.
The confusion between the two causes real distress. So confirm which one your team is describing.
Why it exists
Prostate cancer is common and much of it is slow. Screening finds many cancers that would never have caused symptoms in a man's lifetime. Surgery and radiation carry real risks. Those include urinary leakage, erectile dysfunction, and bowel side effects. Active surveillance exists so you do not pay those costs for a cancer that was not going to harm you.
The ProtecT trial studied men with localized prostate cancer found by PSA screening. It randomly assigned them to active monitoring, surgery, or radiotherapy. At 15 years, prostate-cancer-specific survival was about 97% in all three groups. There were 17 deaths in the monitoring arm, 12 after prostatectomy, and 16 after radiotherapy. Metastases were more frequent with monitoring: 9.4%, versus 4.7% after surgery and 5.0% after radiotherapy. About a quarter of men in the monitoring arm were still alive without any prostate cancer treatment at the end of follow-up.
That is the honest trade-off. Deferring treatment did not increase the chance of dying from prostate cancer over 15 years. It did roughly double the chance of developing metastatic disease. And it spared many men treatment side effects entirely. Reasonable people weigh those differently.
Who is generally considered
Active surveillance is most established for Gleason grade group 1 (Gleason 6) disease. It also calls for PSA under 10, limited cancer on biopsy, and clinical stage T1c or T2a. Some men with grade group 2 (Gleason 3+4) and favorable features are offered it too. That is more likely where the pattern 4 component is small.
Other information often factors in. MRI findings, PSA density and genomic tests on biopsy tissue all count. So do family history and germline genetic results such as BRCA2, which may push toward treatment. Life expectancy matters too.
What the protocol looks like
Programs vary between centers. A typical schedule includes:
- PSA every 6 months, sometimes every 3 months at first.
- Digital rectal examination roughly annually.
- Multiparametric MRI at intervals, often at entry and then every 1 to 3 years or when something changes.
- Confirmatory biopsy within the first 6 to 18 months, because initial biopsies can miss higher-grade disease.
- Surveillance biopsies thereafter, commonly every 2 to 5 years, or targeted biopsy prompted by MRI or PSA changes.
The confirmatory biopsy matters more than people expect. A meaningful minority of men are reclassified to higher-grade disease on it. That is exactly what it is designed to find.
What triggers a change
Several findings prompt a treatment discussion. A biopsy may show a higher Gleason grade group. The amount of cancer may increase substantially. MRI may show a growing or newly suspicious lesion. PSA may rise faster than expected. Or you may decide you no longer want to continue monitoring. That last one is legitimate. Anxiety is a valid reason to change course, and many men do.
Roughly a third to a half of men on active surveillance move to treatment within ten years. Doing so is not a failure of the strategy. It is the strategy working as designed.
Living with it
The demands are real. There are appointments and repeat biopsies. And you hold a cancer diagnosis without treating it. Biopsies carry small risks of infection and bleeding. Some men find the monitoring itself more stressful than treatment would have been. That is worth naming rather than enduring silently.
Worth asking
Ask whether you are being offered active surveillance or watchful waiting. Ask for the written protocol: what tests, how often, for how long. Ask what specific findings would trigger treatment. Ask whether MRI and genomic testing are part of your program. Ask what happens to your treatment options if you defer for several years.
Sources
Words to know
Tap any term to see what it means.
Common questions
Is active surveillance the same as watchful waiting?
No, and the confusion causes real distress. Active surveillance is intensive monitoring with the intent to cure if things change. Watchful waiting is looser monitoring, usually where curative treatment would not benefit someone because of age or other conditions, with the goal of managing symptoms. Confirm which your team means.
Am I taking a risk by not treating now?
There is a real trade-off. In ProtecT, deferring treatment did not increase prostate cancer death over 15 years, and it roughly doubled the chance of developing metastatic disease, while sparing many men treatment side effects entirely. Reasonable people weigh those differently, and it is your call to make with your team.
Why do I need another biopsy so soon?
The confirmatory biopsy is designed to catch higher-grade cancer that the first biopsy missed, and a meaningful minority of men are reclassified on it. It is one of the most useful steps in the whole protocol.
What would make me switch to treatment?
Commonly a higher Gleason grade group on biopsy, a substantial increase in the amount of cancer, a growing or newly suspicious lesion on MRI, PSA rising faster than expected, or your own decision that you no longer want to continue monitoring. That last reason is legitimate.
Can I stop surveillance if the anxiety is too much?
Yes. Anxiety is a valid reason to change course, and many men do. Some find the monitoring itself more stressful than treatment would have been. Naming this to your team is better than enduring it silently.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Written by: Cancer ExplainedSources last checked: 2026-07-30 what this meansLast updated: 2026-08-10Next planned review: 2027-01-30
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share